TrialBritish journal of cancer2026

Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.

Jiajia Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.